SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Greed Is Good who wrote (325)3/31/1998 11:13:00 AM
From: Easy Mark   of 1510
 
Greed - If you search the Web you will find over 100 Aides treatments in various stages of development. Some are unique to HIV and others are related to the general immune response function that has implications for cancer. What is most compelling about Remune is that it is specifically targeting the resevoir of virus that hides inside the immune cells themselves. By thus hiding, Aides escapes both the body's immune response and the triple drup therapy. I have been able to find only one other company targeting this same phenomena (Cell Genesys), but they are far behind Remune in demonstrating safety. I think in the final call by FDA, the key issue will be that Remune at worst does no harm, and at best is the key to killing the last virus resevoir. Since approval of Remune would not cause any patients to forgo treatment of other therapies the case for not approving Remune seems weak.
P.S. If you are angry, its time to exit the stock for you. My advice is to bet the probabilities on clinical outcomes and not to try to beat the traders at their inside games. On average you will lose for the same reason that casinos win. I do agree that IRC has blundered by creating shareholder expectations for a collaboration which at best is later than they said. As I pointed out in my earlier message, the economic effect on the stock value is minimal, but it could be exacerbated by stockholders who felt they were misled by IRC. I believe IRC had good intensions in trying to be forthcoming and state what was going on. But, its better for them to keep silent until they have substantive news. I imagine the big merger discussions among the major drug companies was just as much a surprise to them as to the rest of the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News